AQUABILITI AQUASTAT (MRP) – sodium chloride issues (2023)
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
AQUABILITI AQUASTAT 0.9% Sodium Chloride Injection syringe, USP, 5mL in 12mL, REF 2T0805; and 3mL in 12mL, REF 2T0807, intermediate cartons containing 100 syringes, shipping cases containing 400 syringes, Rx, Sterile.
Brand
MRP, LLC dba Aquabiliti
Lot Codes / Batch Numbers
REF 2T0805 - Lot numbers KH04910, exp. 1/11/2024, KH04930, exp. 3/13/2024, KH04954, exp. 5/22/2024, KH04975, exp. 8/2/2024, KH04990, exp. 9/6/2024, KH05020, exp. 10/23/2024, KH05022, exp. 10/24/2024, KH05043, exp. 11/13/2024, KH05066, exp. 12/13/2024, KH05068, exp. 12/14/2024, KH05070, exp. 12/18/2024, KH05073, exp. 12/20/2024, KH05134, exp. 6/25/2025, KH05135, exp. 6/27/2025, and KH05152, exp. 10/10/2025, UDI-DI 10859809005013. REF 2T0807 - Lot numbers KH04909, exp. 1/10/2024, KH04944, exp. 4/24/2024, KH04986, exp. 8/30/2024, KH04988, exp. 9/5/2024, KH05024, exp. 10/25/2024, KH05026, exp. 10/26/2024, and KH05071, exp. 12/19/2024, UDI-DI 10859809005037.
Products Sold
REF 2T0805 - Lot numbers KH04910, exp. 1/11/2024; KH04930, exp. 3/13/2024; KH04954, exp. 5/22/2024; KH04975, exp. 8/2/2024; KH04990, exp. 9/6/2024; KH05020, exp. 10/23/2024; KH05022, exp. 10/24/2024; KH05043, exp. 11/13/2024; KH05066, exp. 12/13/2024; KH05068, exp. 12/14/2024; KH05070, exp. 12/18/2024; KH05073, exp. 12/20/2024; KH05134, exp. 6/25/2025; KH05135, exp. 6/27/2025; and KH05152, exp. 10/10/2025; UDI-DI 10859809005013. REF 2T0807 - Lot numbers KH04909, exp. 1/10/2024; KH04944, exp. 4/24/2024; KH04986, exp. 8/30/2024; KH04988, exp. 9/5/2024; KH05024, exp. 10/25/2024; KH05026, exp. 10/26/2024; and KH05071, exp. 12/19/2024; UDI-DI 10859809005037.
MRP, LLC dba Aquabiliti is recalling AQUABILITI AQUASTAT 0.9% Sodium Chloride Injection syringe, USP, 5mL in 12mL, REF 2T0805; and 3mL in due to The saline flush syringes may fail to meet USP criteria for stated sodium chloride content after 12 months.. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
The saline flush syringes may fail to meet USP criteria for stated sodium chloride content after 12 months.
Recommended Action
Per FDA guidance
The recalling firm issued a letter dated 12/28/2023 via email. The letter explained the reason for recall, risk to health, and actions to be taken. The actions included the consignee examine their inventory and discontinue distribution and use immediately. All products should be segregated. A Shipment Summary and Acknowledgment Form was enclosed for completion and return to indicate the consignee has read and understands the recall instructions, identified and quarantined the affected product in inventory, and that the consignee has notified their customers who were shipped the product. It goes onto list the specific lot numbers and quantity of affected product sent to the consignee and asks for the quantity of product consumed and the quantity available for return. The letter was also issued via certified mail on 1/4/2024. The firm issued a corrected letter dated 1/8/2024 to correct the table listing lot numbers on Page 2 of the letter. Those lot numbers were asterisked for ease of identification by the consignee. The lot numbers listed on the Shipment Summary and Acknowledgment Form were correct in the original letter.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 10, 2026